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ABSTRACT
Yeast cells expressing the Glu418Lys human topoi-
somerase I mutant display a camptothecin resis-
tance that slowly decreases as a function of time.
Molecular characterization of the single steps of the
catalytic cycle of the purified mutant indicates that it
has a relaxation activity identical to the wild-type
protein but a different DNA sequence specificity for
the cleavage sites when compared to the wild-type
enzyme, as assayed on several substrates. In
particular the mutant has a low specificity for CPT
sensitive cleavable sites. In fact, the mutant has, at
variance of the wild-type enzyme, a reduced pre-
ference for cleavage sites having a thymine base in
position  1 of the scissile strand. This preference,
together with the strict requirement for a thymine
base in position  1 for an efficient camptothecin
binding, explains the temporary camptothecin resis-
tance of the yeast cell expressing the mutant and
points out the importance of the DNA sequence in
the binding of the camptothecin drug.
INTRODUCTION
Human topoisomerase I controls the superhelical structure of
DNA playing a critical role in important biological processes,
such as DNA replication, transcription and recombination
(1–3). The enzyme is composed of 765 amino acids and
has four distinct domains: the NH2-terminal domain
(1–214), the core domain (215–635), the linker domain
(636–712) and the COOH-terminal domain (713–765) (4–6).
The outline of the catalytic cycle has been unveiled in
recent years. The active site tyrosine (Tyr-723) starts the
catalytic cycle of the enzyme through a nucleophilic attack
on the DNA backbone, resulting in the breakage of one
DNA strand and formation of a covalent intermediate
between the enzyme and the DNA 30-phosphate. After
changing the linking number a second nucleophilic attack,
driven by the 50-hydroxyl DNA end, restores an intact
double-stranded DNA, after which the enzyme is released.
The covalent intermediate between topoisomerase I and
DNA is a transient step and when CPT is added the cleavage-
religation equilibrium is shifted toward cleavage. Collision
between the stabilized covalent complex intermediate and
the replication fork results in double-strand DNA breaks
and triggers a cascade of event leading to apoptosis (1,7).
The X-ray diffraction study of the ternary complex formed
by the human topoisomerase I, bound to the preferred
sequence double-strand DNA with CPT or topotecan, a
CPT derivative in clinical use as an anticancer agent (8,9),
has provided details of the interaction of the drug with the
catalytic region, proposing a molecular explanation for the
resulting slowdown of the religation step.
Several topoisomerase I mutations, located either near or
far from the active site, have been shown to render the
enzyme resistant to the drug (8,10). The 3D structures of
the ternary complexes with the native enzyme (5) and with
some speciﬁc mutants (8,10,11) have clariﬁed the molecular
basis for the resistance for most of the mutations located near
the active site, but have still left unexplained the effects of
those located far from it, such as the Ala653Pro, the
Glu418Lys and the Thr729Ala mutants (12–14). In the case
of the Ala653Pro mutation, a combined experimental and
simulative approach has demonstrated that the drug resistance
is correlated to a difference in linker mobility that induces
an altered control of the religation process (12), indicating
the importance of the protein concerted motions in the
catalytic cycle. The combined use of experimental and theo-
retical techniques has been adopted also for the characteriza-
tion of functional and dynamical properties of the human
topoisomerase I Thr718Ala mutant, which shows a lethal
phenotype (15).
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Glu418Lys mutant, previously identiﬁed in a CPT-resistant
clone of a human nasopharyngeal carcinoma treated for a
long period with a CPT derivative (13). Our results indicate
that the yeast cells expressing the mutant show a time-
dependent resistance to CPT and that the puriﬁed mutant
displays a different cleavage pattern compared to the wild-
type enzyme. The Glu418Lys mutant, in particular, shows a
larger preference for CPT unsensitive sites, as the ones
having a thymine base in position  1 of the scissile strand
(16), providing an explanation for the temporary drug resis-
tance observed in yeast cells expressing the mutant.
MATERIALS AND METHODS
Yeast strains and plasmids
Camptothecin (Sigma) was dissolved in Me2SO to a ﬁnal
concentration of 4 mg/ml and stored at  20 C. Anti-FLAG
M2 afﬁnity gel, FLAG peptide and M2 monoclonal antibody
were purchased from Sigma. Saccharomyces cerevisiae
strains JN2-134 (MATa rad52::LEU2, trp1, ade2-1, his7,
ura3-52, ise1, top1, leu2) and EKY3 (ura3-52, his3D200,
leu2D1, trp1D63, top1::TRP1, MATa) were described
previously (17,18). Plasmid YEpGAL1-wild-type and
YCpGAL1-wild-type in which the human topoisomerase I
is expressed under the galactose inducible promoter in a
multi-copy plasmid was described previously (19).
Glu418Lys was generated by oligonucleotide-directed muta-
genesis of the YEpGAL1-wild-type and YCpGAL1-wild-
type. The epitope-tagged construct YEpGAL1-e-wild-type
contains the N-terminal sequence FLAG: DYKDDDY
(indicated with ‘e’), recognized by the M2 monoclonal anti-
body. The epitope-tag was subcloned into YEpGAL1-
Glu418Lys to produce YEpGAL1-e-Glu418Lys.
Drug sensitivity
Cultures of JN2-134 transformed with plasmids YEpGAL1-
wild type, YEpGAL1-Glu418Lys and YEpGAL1 were
grown at an OD A595 of 0.3, serially 10-fold diluted, and
5 ml spotted onto selective media containing dextrose or
galactose. CPT sensitivity was assayed on dextrose plates
containing 25 mM HEPES (pH 7.2) and 0.5 mg/ml CPT.
Plates were incubated at 30 C for 3 days.
Cell viability assay
Overnight cultures of EKY3 transformed with plasmids
YCpGAL1-wild-type, YCpGAL1-Glu418Lys, YCpGAL1-
Ala653Pro (12) and YCpGAL1 were diluted 1:100 into selec-
tive media containing 2% rafﬁnose. At an A595 of 0.3 the
cultures were induced for 1 h with 2% galactose. After induc-
tion, cells were treated with 50 mM CPT or 1% Me2SO. At
various time points aliquots were serially diluted and plated
onto selective media containing 2% dextrose. The number
of colonies was counted following incubation at 30 C and
plotted relative to the number obtained at time 0 (drug
addition).
Purification of DNA topoisomerase I
To purify the topoisomerase I epitope tagged EKY3 cells
were transformed with YEpGAL1-e-wild-type and
YEpGAL1-e-Glu418Lys, grown on SC-uracil plus 2%
dextrose and diluted 1:100 in SC-uracil plus 2% rafﬁnose.
At an OD A595 of 1.0, the cells were induced with 2% galac-
tose for 6 h. Cells were then harvested by centrifugation,
washed with cold water and resuspended in 2 ml buffer/g
cells using a buffer containing 50 mM Tris (pH 7.4), 1 mM
EDTA, 1 mM ethylene glycol-bis(2-aminoethylether)-
N,N,N0,N0-tetraacetic acid, 10% (v/v) glycerol completed
with protease inhibitors cocktail (Roche 1 836 153) and sup-
plemented with 0.1 mg/ml sodium bisulﬁte and 0.8 mg/ml
sodium ﬂuoride. After addition of 0.5 vol of 425–600 mm
diameter glass beads the cells were disrupted by vortexing
for 30 s alternating with 30 s on ice. The lysate was cen-
trifuged and KCl ﬁnal concentration 0.15 M was added to
the sample before loading onto 2 ml ANTI-FLAG M2 Afﬁn-
ity Gel column equilibrated as described in the technical
bulletin (Sigma). The column was washed with 20 column
volumes of TBS [50 mM Tris–HCl and 150 mM KCl
(pH 7.4)]. Elution of FLAG-fusion topoisomerase I was per-
formed by competition with ﬁve column volumes of a solu-
tion containing 100 mg/ml FLAG peptide in TBS. Fractions
of 500 ml were collected and glycerol ﬁnal concentration
40% was added; all preparations were stored at  20 C.
The fractions were resolved by SDS–PAGE; protein concen-
tration and integrity were measured through immunoblot
assay, using the epitope-speciﬁc monoclonal antibody M2.
After normalization to the same amount of protein, the activ-
ity of the wild-type and mutant DNA topoisomerase I, as
assayed by relaxation of supercoiled DNA in 150 mM KCl,
was found to be almost identical. In all the biochemical
experiments the same amount of wild-type and mutated pro-
tein has been used.
DNA topoisomerase I activity in vitro
Topoisomerase I activity was assayed with a DNA relaxation
assay (17–20). Topoisomerase I preparations were incubated
in 30 ml reaction volume containing 0.5 mg of negatively
supercoiled plasmid pHC624 and reaction buffer [20 mM
Tris–HCl (pH 7.5), 0.1 mM Na2EDTA, 10 mM MgCl2,
50 mg/ml acetylated BSA and 150 mM KCl). Moreover, to
assess the effects of ionic strength on enzyme activity KCl
was added in the DNA relaxation assay. Reactions were
stopped with a ﬁnal concentration of 0.5% SDS after 1 h at
37 C and electrophoresis of the samples was carried out in
a 1% agarose gel.
Kinetics of cleavage using oligonucleotide substrate
Oligonucleotide substrates CL14 (50-GAAAAAAGACTT-
AG-30) or CL14-A (50-GAAAAAAGACATAG-30) or CL-
14-G (50-P-GAAAAAAGACGTAG-30) were radiolabelled
with [g-
32P]ATP at their 50 end. The CP25 complementary
strand (50-TAAAAATTTTTCTAAGTCTTTTTTC-30) or the
CP25-T (50-TAAAAATTTTTCTATGTCTTTTTTC-30)o r
the CP25-C (50-TAAAAATTTTTCTACGTCTTTTTTC-30)
were phosphorylated at their 50 end with unlabelled ATP.
CL14/CP25 or CL14-A/CP25-T or CL14G/CP25C were
annealed as described previously (12). The suicide cleavage
reactions were carried out by incubating 20 nM of the duplex
with an excess of enzyme in 20 mM Tris (pH 7.5), 0.1 mM
Na2EDTA, 10 mM MgCl2,5 0mg/ml acetylated BSA and
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by Yang and Champoux (21). A 5 ml sample of the reaction
mixture was removed before addition of the protein and used
as the zero time point. At various time points 5 ml aliquots
were removed and the reaction stopped with 0.5% SDS.
After ethanol precipitation samples were resuspended in
5 ml of 1 mg/ml trypsin and incubated at 37 C for 30 min.
Samples were analyzed by denaturing urea/PAGE. The per-
centage of CL1 or CL2 were determined by PhosphorImager
and ImageQuant software and normalized on the total amount
of radioactivity in each lane.
Kinetics of religation using oligonucleotide substrate
CL14/CP25 (20 nM), prepared as described above was incu-
bated with an excess of enzyme for 60 min at 23 C followed
by 30 min at 37 C in 20 mM Tris (pH 7.5), 0.1 mM
Na2EDTA, 10 mM MgCl2,5 0mg/ml acetylated BSA and
150 mM KCl. Religation reactions were initiated by adding
a 200-fold molar excess of R11 oligonucleotide (50-AGAAA-
AATTTT-30) or R13 (50-TTAGAAAAATTTT-30) over the
duplex CL14/CP25 in the presence or absence of 100 mM
CPT. At 37 C a various time point 5 ml aliquots were
removed and the reaction stopped with 0.5% SDS. After
ethanol precipitation samples were resuspended in 5 mlo f
1 mg/ml trypsin and incubated at 37 C for 30 min. Samples
were analyzed by denaturing urea/PAGE. The percentage of
the remaining covalent complex (CL1 or CL2) was deter-
mined by PhosphorImager and ImageQuant software and
normalized on the total amount of radioactivity in each lane.
Cleavage/religation equilibrium
Oligonucleotide CL25 (50-GAAAAAAGACTTAGAAAAA-
TTTTTA-30) was radiolabelled with [g-
32P]ATP at its 50
end. The CP25 complementary strand (50-TAAAAATTTTT-
CTAAGTCTTTTTTC-30) was phosphorylated at its 50 end
with unlabelled ATP. The two strands were annealed at a
2-fold molar excess of CP25 over CL25. A ﬁnal concentra-
tion of 20 nM duplex CL25/CP25 was incubated with an
excess of enzyme at 25 C in 20 mM Tris (pH 7.5), 0.1 mM
Na2EDTA, 10 mM MgCl2,5 0mg/ml acetylated BSA and
150 mM KCl, in the presence or absence of 1, 2.5, 5, 10,
30 mM CPT. After 30 min, the reaction was stopped by
adding 0.5% SDS and digested with trypsin after ethanol
precipitation. Reaction products were resolved in 16%
acrylamide-7 M urea gels and the percentage of cleavage
was determined by PhosphorImager and ImageQuant
software.
The cleavage religation equilibrium was also assayed incu-
bating enzyme preparations with a 900 bp double-stranded
DNA fragment, radiolabelled at one unique 30 end, in the
presence or absence of CPT. The 900 bp DNA fragment, con-
taining a high afﬁnity DNA topoisomerase I cleavage site,
was single
32P-end-labelled and puriﬁed from plasmid
pBlueAK3-1 as described (20). Enzyme preparations were
incubated in 20 ml reactions with DNA, reaction buffer and,
where indicated, 1 mM CPT. Dimethyl sulfoxide (DMSO)
was added to the no-drug controls. Following 8 min of
incubation at 37 C in the case of no drug experiment, and
0.25, 1, 4 or 8 min, for kinetic assay in the presence of
CPT, reactions were stopped by the addition of 1% SDS.
The cleaved DNA fragments were resolved in 7 M urea/8%
polyacrylamide gels and visualized by phosphorimager.
RESULTS
The Glu418Lys mutant is active and partially resistant
to CPT in yeast cells
The resistance and the in vivo activity of Glu418Lys topoiso-
merase I mutant has been tested in a yeast drug sensitivity
assay which makes use of the JN2-134 (rad52D) strain that
does not tolerate galactose induced topoisomerase I expres-
sion from a multicopy vector and that, due to the leaky
expression of the same vector, is sensitive to CPT (22).
Figure 1A, showing the result for the wild-type and the
Glu418Lys mutant, indicates that substitution of the glutamic
418 residue with a lysine confers slight resistance, and also
demonstrates that the mutant is active in vivo because
the yeast strain dies when the enzyme is overexpressed on
galactose.
To better elucidate the partial drug resistance, a cell viabil-
ity assay in liquid culture has been carried out. EKY3 cells
Figure 1. Glu418Lys is partially resistant to CPT in vivo.( A) Exponentially
growing cells in dextrose, transformed with YEpGAL1-wild-type,
YEpGAL1-Glu418Lys or YEpGAL1 (vector), serially 10-fold diluted starting
from an A595 of 0.3; 5 ml, and spotted onto selective media in the presence of
dextrose (left) or dextrose plus 0.5 mg/ml CPT (middle), or induced with
galactose (right). (B) Number of colonies relative to that obtained at time 0
plotted against time for wild-type, (circle), Glu418Lys mutant (square),
Ala653Pro mutant (diamond) and vector (triangle). Exponentially growing
cells in dextrose transformed with YCpGAL1-wild-type, YCpGAL1-
Glu418Lys, YCpGAL1-Ala653Pro or YCpGAL1 (Vector) were diluited
1:100 into selective medium containing 2% raffinose. After induction with
2% galactose cells were treated with 50 mM CPT or 1% Me2SO. At various
time point aliquots were serially diluted and plated onto selective media
containing 2% dextrose. Three different plates were averaged for each data
point, and the error bars indicate the standard deviation of the individual
values from the mean.
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Glu418Lys or wild-type or Ala653Pro (that is known to be
CPT resistant) (12), or the vector were induced with galactose
and treated with 50 mM CPT. At various time intervals,
aliquots were removed and plated onto selective medium to
score for viable cells. Figure 1B shows that the cells express-
ing the Glu418Lys mutant display a time-dependent CPT
resistance. In fact the Glu418Lys expressing cells in the
ﬁrst 2 h are increasing in numbers just like the Ala653Pro
expressing cells. However, at longer times, the Ala653Pro
transformed cells continue their growth, while the Glu418Lys
transformed ones gradually stop growing, indicating the
occurrence of a time dependent process that renders them
sensitive to CPT. After 6–8 h of treatment with CPT, the
Glu418Lys viable cells reach the same level of drug sensitiv-
ity as the cells expressing the wild-type protein. This experi-
ment conﬁrms that the Glu418Lys mutant is active in vivo
and indicates the existence of a molecular mechanism that
permits the survival of the cells expressing the mutated
enzyme only during the ﬁrst hours from drug addition, slowly
switching them toward CPT sensitivity. It can be excluded
that the time-dependent survival of the yeast cells expressing
the Glu418Lys mutant is due to a slow uptake of CPT since
the yeast cells expressing topoisomerase I wild-type or the
Ala653Pro mutant display a fast, not time-dependent,
response to the drug, positive or negative, respectively.
The catalytic activity of the Glu418Lys mutant has also
been tested in vitro, serially diluting and incubating identical
wild-type and mutant protein concentrations with the same
amount of supercoiled plasmid DNA. The Glu418Lys mutant
shows a relaxation efﬁciency similar to the wild-type protein,
as well as the same ionic strength dependence (data not
show). In fact, relaxation experiments carried out at salt
concentration ranging between 50 and 300 mM show that
the mutant Glu418Lys and the wild-type enzymes have an
identical salt dependent relaxation efﬁciency, indicating that
the single mutation apparently does not perturb the electro-
static interaction between the enzyme and the DNA, despite
the fact that the mutation involves a net charge difference.
Effect of CPT on the cleavage-religation equilibrium
To investigate the mechanism of time dependence of the
Glu418Lys mutant camptothecin resistance, the stability of
the covalent DNA–enzyme complex has been analyzed
using the 25mer full duplex oligonucleotides substrate
CL25/CP25 in the absence or presence of increasing amount
of CPT (from 1 to 30 mM). After 30 min of incubation, the
reactions were stopped with SDS, the samples were treated
with trypsin and the products analyzed by polyacrylamide–
urea gel electrophoresis (Figure 2). The results, in the absence
of the drug, are consistent with the ﬁnding that the cleavage-
religation equilibrium is shifted toward religation for the
wild-type protein, not being detectable any trapped cleavable
complex (Figure 2, lane 1). When the wild-type protein is
exposed to increasing amount of CPT the cleavage-religation
equilibrium is shifted toward the cleavage as already reported
(23,24), since the band corresponding to the substrate cleaved
at the preferred CL1 site is clearly detectable (Figure 2,
lanes 2–6). The Glu418Lys mutant in the absence of CPT,
shows an equilibrium shifted toward religation as that of
the wild-type protein (Figure 2, lane 7). In the presence of
increasing amount of CPT the equilibrium is partially shifted
toward cleavage as revealed by the substrate band appearing
on the gel (Figure 2, lanes 8–12), i.e. less intense than for the
wild-type, indicating that the Glu418Lys mutant is less sensi-
tive to the drug, although it is still able to bind CPT and
stabilize the cleavable complex. To better clarify this point
and since the equilibrium constant Keq is given by the ratio
between the cleavage and the religation rate (kcl/kr), the single
steps of the enzyme catalytic cycle have been analyzed.
Cleavage of the wild-type and Glu418Lys mutant with
the preferred CL14/CP25 substrate
The time course of the cleavage of the wild-type and
Glu418Lys mutant has been followed using a suicide cleav-
age substrate. In detail, a 50 end radiolabelled oligonucleotide
CL14 (50-GAAAAAAGAC*TT
#AG-30) has been annealed
to the CP25 (50-TAAAAATTTTTCTAAGTCTTTTTTC-30)
complementary strand, to produce a duplex with an 11 base
50 single-strand extension. The arrow identiﬁes the preferred
cleavage (CL1) site for the enzyme, but the wild-type enzyme
has been shown to cleave the oligonucleotide also at the site
indicated by the asterisk (CL2), although to a lower extent
(23). The religation step is precluded because the AG-30 or
TTAG-30 oligonucleotides are too short to be religated,
leaving the enzyme covalently attached to the 12 or 10
oligonucleotide 30 end (23).
The suicide substrate was incubated with an excess of
wild-type or mutant enzyme in a time course experiment.
The cleaved DNA fragments resolved in a denaturing
polyacrylamide gel are reported in Figure 3A. The cleavage
reaction is very fast for both the wild-type and the mutant
enzyme, with all the substrate already cleaved within 15 s,
Figure 2. Cleavage/religation equilibrium of the CL25/CP25 fully duplex
DNA substrate. Gel electrophoresis of the products coming from the
incubation of the wild-type topoisomerase I with the [g-
32P] end-labelled
duplex DNA, shown at the top of the figure in the absence (lane 1) and
presence (lanes 2–6) of increasing amount of CPT. The arrow at the DNA
sequence indicates the CL1 site preferred by the wild-type protein. Lanes 7
and 8–12 show the same experiment with the Glu418Lys mutant. The asterisk
indicates the band corresponding to the CL1 site.
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(kcl). However, evaluation of the cleavage products, namely
CL1 and CL2, indicates that the wild-type and mutated
enzymes have different substrate distributions (Figure 3B).
In fact, both enzymes give an identical percentage of total
cleavage products but the wild-type enzyme, as shown in
Figure 3B, preferentially cuts ( 85%) at the CL1 site (full
vertical lines) and only moderately ( 15%) at the CL2 site
(dashed vertical lines), whilst the mutated enzyme equally
cuts at the CL1 (full horizontal lines) and the CL2 (dashed
horizontal lines) sites. So a clear effect of the Glu418Lys
mutation is to induce different substrate speciﬁcity. The
DNA base cleavage preferences, studied for the wild-type
topoisomerase I in the SV40 genome (16), has indicated
that the enzyme shows a strong preference for T in position
 1 in the scissile strand, as in the CL1 but not in the CL2
site, that has a C base in this position. The mutant then
reduces the enzyme cleavage preference for a thymine base
in position  1 in the scissile strand.
Religation of the wild-type and Glu418Lys mutant
Because of the different substrate speciﬁcities displayed by
the wild-type and mutated enzyme, the DNA religation step
has been studied for both enzyme by adding R11 (50-AGAA-
AAATTTT-30) or R13 (50-TTAGAAAAATTTT-30) oligonu-
cleotides, that can bind to the CL1 or the CL2, respectively.
The wild-type and mutant enzyme have been incubated for
60 min with the suicide substrate in order to generate the
cleavage complexes. Once cleavage has occurred, R11 or
R13 oligonucleotide are added to start the religation
process in the absence or presence of 100 mM CPT. Aliquots
have then been removed as function of time, the reaction
stopped by SDS, trypsinized, analyzed by PAGE and the
percentage of the remaining cleaved 1 or 2 complexes has
been plotted. Figure 4A shows the religation kinetics upon
addition of the R13 oligonucleotide. The CL1 band maintains
the same intensity at different times, indicating that R13 is
religated by the enzyme only at the CL2, whose band
decreases in intensity as a function of time. As indicated
in Figure 4B, the percentage of the remaining cleaved com-
plex 2 as a function of time indicates that, in the absence
of CPT, the religation rate of the Glu418Lys mutant (full
red line) is faster than the wild-type enzyme (full black
line). The presence of the drug does not affect the religation
rate of the wild-type protein (black dashed lines) and only
slightly that of the Glu418Lys mutant (dashed red line), as
quantiﬁed and normalized on the total amount of radioactivity
in each lane (Figure 4B). This result indicates that the binary
Figure 3. Suicide cleavage experiment with the CL14/CP25 substrate for the
wild-type and Glu418Lys mutant. (A) Time course of the suicide cleavage
reaction carried out with the substrate described on the top of the figure. CL1
and CL2 identify the cleaved complexes at the site indicated by the arrow and
the asterisk, respectively. Lane C, no protein added. (B) Percentage of the
DNA substrate cleaved at the CL1 or CL2 site for the wild-type and the
Glu418Lys mutant.
Figure 4. Religation experiment with the R13 oligonucleotide for the wild-
type and Glu418Lys topoisomerase I. (A) Time course of the religation
experiment between the R13 substrate and the wild-type or Glu418Lys
covalent complexes, in the absence or presence of 100 mM CPT. The R13
oligonucleotide is selectively religated to the CL2 site but not to the CL1 site.
(B) Percentage of the remaining covalent complex 2 plotted at different time
for the wild-type and Glu418Lys (black and red lines, respectively), in
absence (full line) and presence (dashed line) of CPT. Three different
religation experiments were averaged for each data point, and the error bars
indicate the standard deviation of the individual values from the mean.
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cytosine base in the  1 position, is not stabilized by CPT
for both proteins. In line, previous experimental data (16),
partially conﬁrmed by a theoretical study (25) have shown
that a thymine base in position  1 of the scissile strand is
a strict requirement for CPT activity.
The religation experiment carried out upon addition of the
R11 oligonucleotide is shown in Figure 5A. The intensity of
the CL2 band is fairly constant at any time indicating that the
R11 is religated only at the CL1 site. The plot of the percent-
age of the remaining CL1 (Figure 5B) indicates that in the
absence of CPT the rate of religation is almost identical for
both enzymes (full black and red lines). The addition of
CPT abolishes the religation process in the ﬁrst 30 s for the
wild-type protein (dashed black line) and strongly reduces
that of the Glu418Lys mutant (dashed red line), indicating
that CPT is able to bind and inhibit the religation process
for both enzymes.
Confirmation of the different cleavage specificity of the
Glu418Lys mutant
Different oligonucleotide substrates have been used in order
to verify that the different sequence speciﬁcity of the mutant
in respect of the wild-type is observed not only with the pre-
ferred CL14/CP25 substrate. Figure 6 shows the cleavage
reaction with two different suicide substrates CL14-A/
CP25-T and CL14-G/CP25-C, where a thymine in position
+1 in respect of the CL2 site has been substituted with an ade-
nine or a guanine, respectively. The experiment conﬁrms the
different sequence speciﬁcity of the mutant, and most impor-
tant it shows that for both substrates the cleavage at the CL1
site, i.e. at a site having a thymine base in position  1 in the
scissile strand, is much reduced in the mutant when compared
to the wild-type enzyme. Actually in the case of the CL14-G/
CP25-C substrate the mutant never cleaves at the CL1 site. It
is interesting to notice that the cleavage reaction is slower,
when compared with the one carried out with the CL14/
CP25 substrate for both the wild-type and the mutated
enzymes. In fact, Figures 3 and 6 have a time scale of seconds
and minutes, respectively.
Different sequence speciﬁcity is also shown by the
cleavage-religation experiments carried out as a function of
time for both enzymes with a linear 900 bp oligonucleotide,
in absence or in presence of 1 mM of CPT (Figure 7). The
experiment shows in the case of the wild-type the presence
of a large number of bands diagnostic of several CPT trapped
cleavable complexes, much higher than in the case of the
mutant. Actually at short times, in the case of the mutant
only few bands are barely detectable, that partially increase
as a function of time, indicating that the mutant is able to
cleave only at few CPT sensitive sites.
DISCUSSION
The results presented here provide a molecular explanation
for the slight CPT resistance of the Glu418Lys mutant of
topoisomerase I, ﬁrst reported by Chang et al. (13) and con-
ﬁrmed by the assay shown in Figure 1A. Interestingly the
mutation doesn’t affect enzyme activity in vivo and in vitro,
as shown by the death of the yeast strain when the mutant is
overexpressed on galactose (Figure 1A) and by in vitro plas-
mid relaxation assay (data not shown). Yeast EKY3 cells,
expressing the Glu418Lys mutant, show a CPT resistance
in the ﬁrst 2 h, but after this time the resistance starts to
decrease, reaching the same level of sensitivity of the cells
expressing the wild-type protein after 6–8 h of treatment
Figure 5. Religation experiment with the R11 oligonucleotide for the wild-
type and Glu418Lys topoisomerase I. (A) Time course of the religation
experiment between the R11 substrate and the wild-type or Glu418Lys
covalent complexes, in the absence or presence of 100 mM CPT. The R11
oligonucleotide is selectively religated to the CL1 site but not to the CL2 site.
(B) Percentage of the remaining covalent complex 1 plotted at different time
for the wild-type and Glu418Lys (black and red lines, respectively), in
absence (full line) and presence (dashed line) of CPT. Note the difference in
scale between this figure and Figure 4. Three different religation experiments
were averaged for each data point, and the error bars indicate the SD of the
individual values from the mean.
Figure 6. Suicide cleavage experiment with the CL14-A/CP25-T or the
CL14-G/CP25-C substrates for the wild-type and Glu418Lys mutant. Left
side: time course of the suicide cleavage reaction carried out with the CL14-
A/CP25-T substrate, described on the top of the figure. CL1 and CL2 identify
the cleaved complexes at the site indicated by the arrow and the asterisk,
respectively. Lane C, no protein added. Right side: time course of the suicide
cleavage reaction carried out with the CL14-G/CP25-C substrate, described
on the top of the figure.
5098 Nucleic Acids Research, 2006, Vol. 34, No. 18with CPT (Figure 1B). In a similar assay, carried out by
Chang and co-authors, the time dependence of the CPT resis-
tance was not observed, likely because a different yeast strain
(JN2134) (17) was used (13).
The mutated amino acid is located in the highly conserved
subdomain I of the core domain, on the loop formed by
residues Thr417-Ser423 that directly contacts Lip 1 (see
Figure 8). The loop, located between b strands 10 and 11,
also contacts the  1 and  2 DNA bases in the intact strand
by means of both direct and water mediated hydrogen bonds
(5,26). Based on structural consideration, it has been pro-
posed that the Glu418Lys mutation would disrupt the order
of the 417–423 loop and then the relative positioning of the
Lip 1 region, likely altering a protein-drug contact and so
explaining its resistance to CPT (11). However the equilib-
rium results indicate that CPT is able to interact, altough
with less efﬁciency, with the Glu418Lys mutant, stabilizing
the cleavable complex (Figure 2).
The time-dependent CPT resistance cannot then be simply
explained by the inability of the mutant to interact with CPT,
but can actually be rationalized by the different cleavage spe-
ciﬁcity shown by the Glu418Lys mutant. The ﬁrst important
result is, in fact, that the mutant has a substrate speciﬁcity
very different from that of the wild-type enzyme. In fact, as
shown in Figures 3 and 6, the reaction of the wild-type and
the mutant with three different suicide substrates (CL14/
CP25, CL14-A/CP25-T and CL14-G/CP25-C) produces dif-
ferent pattern distributions. In detail, as shown in Figure 3
and reported in the literature (27), addition of the wild-type
to a CL14/CP25 substrate gives rise to a suicide cleavage
that is mainly ( 85%) localized on the site indicated by the
arrow (CL1) and only in minimal part ( 15%) on the site
indicated by the asterisk (CL2). Pommier and coauthors
have actually demonstrated that a T base in position  1i n
the scissile strand is strongly preferred in the cleavage
process (16). The Glu418Lys mutant loses this preference
being the cleavage distribution over the CL1 and CL2 sites
almost identical (Figure 3). This result is conﬁrmed by the
cleavage experiment carried out with the CL14-A/CP25-T
and CL14-G/CP25-C substrates. In this case the CL1 band
is almost absent in the gel referring to the mutant
(Figure 6) despite the fact that the base mutation is in prox-
imity of the CL2 site. A general feature of the Glu418Lys
mutation is then to reduce the enzyme cleavage preference
for a thymine base in position  1 in the scissile strand.
The religation experiment, carried out on the cleavage
products of the CL14/CP25 substrate, indicates that CPT
strongly inhibits the R11 religation process for both the native
and the mutated enzyme but it is inefﬁcient in inhibiting the
religation of R13 (Figure 4). In fact, the R13 religation occurs
selectively with the oligonucleotide cleaved at the CL2 site,
indicating that CPT is unable to bind this complex. In line
in vivo and in vitro experiments have shown the strict require-
ment of a thymine base in position  1 of the scissile strand in
order to permit CPT binding and stabilization of the binary
complex (16,28). All these ﬁndings provide an explanation
for the time dependent CPT resistance displayed by the cell
expressing the mutant (Figure 1B). In fact, the increased
preference of the mutant for DNA substrates not having a
thymine in position  1 of the scissile strand permits to a
large population of molecules to be cleaved in vivo in
a position that does not permit CPT binding.
The different sequence speciﬁcity of the mutant is also
conﬁrmed by the cleavage/religation equilibrium experiment
of Figure 7, that indicates for the wild-type enzyme the
presence of a large number of CPT sensitive cleavage sites.
Figure 7. Cleavage/religation equilibrium of a 900 bp fully duplex DNA
substrate. Gel electrophoresis of the products coming from the incubation of a
900 bp
32P-end-labelled DNA duplex with the wild-type topoisomerase I
(lanes 1–5) or Glu418Lys mutant (lanes 6–10), as a function of time, in the
absence (lanes 5 and 10) or in the presence of 1 mM CPT (lanes 1–4 and 6–9).
Control, no enzyme added (C). Arrow indicates the preferred cleavage site.
Figure 8. Human topoisomerase I structure in complex with duplex DNA.
The main chain of the 417–423 loop, contacting the intact strand of the lip 1
(represented in red), is shown in yellow. The mutated Glu418 and the
catalytic Tyr723 residues are represented in ball and stick, in green and
yellow colours, respectively. The  1 base of the scissile strand, strictly
required for CPT binding, is coloured in blue; the  1 base of the intact strand,
that contacts the 417–423 loop, is represented in purple. All other enzyme
residues and DNA bases are represented in grey. Core subdomain III is partial
transparent.
Nucleic Acids Research, 2006, Vol. 34, No. 18 5099In the case of the mutant, at short times, just few bands,
diagnostic of the stabilization of a ternary complex, are
detected. Only after some minutes, the mutant cleaves at
sites able to be stabilized by CPT. So we propose that the
number of sites cleaved by the enzyme in CPT sensitive
sequences increase as a function of time, in a way sufﬁcient
to provoke cell death, as shown by the cell viability assay
(Figure 1B). The CPT time dependent resistance of the
Glu418Lys mutant is then due to its different DNA substrate
preference likely induced by the perturbation of the direct
and water mediated interactions of the Thr417-Ser423 loop
with the DNA intact strand (5,26). The indirect effect caused
on the drug binding pocket by the repositioning of Lip 1
should be trascurable, because CPT efﬁciently binds to the
cleavage 1 complex of both the native and the mutated
enzyme, strongly reducing the religation rate of the R11
oligonucleotide in both cases (Figure 5).
In conclusion, we have shown for the ﬁrst time the
occurrence of a different cleavage substrate speciﬁcity for
the single Glu418Lys human topoisomerase I mutant. The
different speciﬁcity points out the important role of core
subdomain I in the substrate recognition and conﬁrms the
strict requirement of T base at the  1 position of the scissile
strand for CPT binding, independently from the 418 residue
nature.
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